Clinical Report: Investigation of Variables Influencing Serum Progesterone Levels

Overview

This study identifies key factors influencing elevated serum progesterone levels on hCG administration day in patients undergoing GnRH antagonist treatment cycles. Significant variables include basal progesterone, hCG-day serum E2 and LH levels, and the total number of oocytes retrieved.

Background

Understanding the factors that influence serum progesterone levels on hCG day is crucial for optimizing assisted reproductive technology (ART) outcomes. Elevated progesterone can adversely affect endometrial receptivity and oocyte quality, leading to decreased pregnancy rates. Identifying these variables allows clinicians to adjust treatment protocols to improve reproductive outcomes.

Data Highlights

Key Findings

• Basal progesterone levels are significantly lower in the normal progesterone group compared to the high progesterone group.
• hCG-day serum E2 and LH levels are independent risk factors for elevated progesterone levels on hCG day.
• Higher BMI is associated with lower progesterone levels, indicating a protective effect.
• Total number of oocytes retrieved correlates positively with elevated progesterone levels.
• Univariate analysis identified multiple factors significantly associated with hCG-day progesterone levels.

Clinical Implications

Clinicians should monitor serum progesterone levels on hCG day to optimize ART outcomes. Adjusting treatment protocols based on identified risk factors, such as BMI and hormone levels, may help mitigate the adverse effects of elevated progesterone on implantation and pregnancy rates.

Conclusion

Strengthen the conclusion by emphasizing the practical applications of the study.

Related Resources & Content

1. Frontiers in Endocrinology, 2025 -- Effect of progesterone levels on the hCG trigger day
2. NG257 Fertility problems: assessment and treatment, NICE, 2026 -- Supporting document for ovarian stimulation
3. Frontiers in Endocrinology, 2026 -- High serum FSH levels on day 7 of stimulation
4. The Journal of Clinical Endocrinology & Metabolism, 2026 -- Oral Elagolix Offers a More Cost-Effective Alternative
5. The Journal of Clinical Endocrinology & Metabolism, 2026 -- Evaluation of Cumulative Live Birth Rates
6. Frontiers in Endocrinology — Comparison of euploidy rates between progestin-primed ovarian stimulation and GnRH antagonist protocols: a single-center study in a mixed-ethnicity population
7. 2025 ESHRE ovarian stimulation update
8. Frontiers | Effect of progesterone levels on the hCG trigger day and the progesterone-to-basal progesterone ratio on pregnancy outcomes in fresh IVF/ICSI cycles with GnRH antagonist protocol: a retrospective cohort study